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Abstract
Aims/hypothesis Distal diabetic sensorimotor polyneuropathy (DSP) is a common complication of diabetes with many patients
showing a reduction of intraepidermal nerve fibre density (IENFD) from skin biopsy, a validated and sensitive diagnostic tool for the
assessment of DSP. Axonal swelling ratio is a morphological quantification altered in DSP. It is, however, unclear if axonal
swellings are related to diabetes or DSP. The aim of this study was to investigate how axonal swellings in cutaneous nerve fibres
are related to type 2 diabetes mellitus, DSP and neuropathic pain in a well-defined cohort of patients diagnosed with type 2 diabetes.
Methods A total of 249 participants, from the Pain in Neuropathy Study (UK) and the International Diabetic Neuropathy
Consortium (Denmark), underwent a structured neurological examination, nerve conduction studies, quantitative sensory testing
and skin biopsy. The study included four groups: healthy control study participants without diabetes (n = 45); participants with
type 2 diabetes without DSP (DSP−; n = 31); and participants with evidence of DSP (DSP+; n = 173); the last were further
separated into painless DSP+ (n = 74) and painful DSP+ (n = 99). Axonal swellings were defined as enlargements on epidermal-
penetrating fibres exceeding 1.5 μm in diameter. Axonal swelling ratio is calculated by dividing the number of axonal swellings
by the number of intraepidermal nerve fibres.
Results Median (IQR) IENFD (fibres/mm) was: 6.7 (5.2–9.2) for healthy control participants; 6.2 (4.4–7.3) for DSP−; 1.3 (0.5–
2.2) for painless DSP+; and 0.84 (0.4–1.6) for painful DSP+. Swelling ratios were calculated for all participants and those with
IENFD > 1.0 fibre/mm. When only those participants with IENFD > 1.0 fibre/mm were included, the axonal swelling ratio was
higher in participants with type 2 diabetes when compared with healthy control participants (p < 0.001); however, there was no
difference between DSP− and painless DSP+ participants, or between painless DSP+ and painful DSP+ participants. The axonal
swelling ratio correlated weakly with HbA1c (r = 0.16, p = 0.04), but did not correlate with the Toronto Clinical Scoring System
(surrogate measure of DSP severity), BMI or type 2 diabetes duration.
Conclusions/interpretation In individuals with type 2 diabetes where IENFD is >1.0 fibre/mm, axonal swelling ratio is related to type
2 diabetes but is not related toDSP or painful DSP.Axonal swellingsmay be an earlymarker of sensory nerve injury in type 2 diabetes.
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Abbreviations
DSP Diabetic sensorimotor polyneuropathy
DSP+ Participants with DSP
DSP− Participants without DSP
IDNC International Diabetic Neuropathy Consortium
IENFD Intraepidermal nerve fibre density
NeuPSIG Neuropathic Pain Special Interest Group
PGP 9.5 Protein gene product 9.5
PiNS Pain in Neuropathy Study
TCSS Toronto Clinical Scoring System
Introduction
Diabetic sensorimotor polyneuropathy (DSP) is a common
complication of diabetes, which typically presents as a distal
symmetric polyneuropathy with sensory loss or pain in the
feet and hands [1, 2]. As currently available treatments for
neuropathic pain demonstrate modest pain relief [3], it is
essential that we improve our understanding of the mecha-
nisms that contribute to painful DSP [2, 4], and understand
why some patients with DSP develop pain and others do not.
Skin nerve fibre morphometric analysis offers potential
insights, as differences are observed between individuals with
painless and painful DSP [5].
Intraepidermal nerve fibre density (IENFD) assessment of
skin biopsy samples is a validated and sensitive diagnostic
tool for the assessment of small fibre neuropathies including
DSP, but IENFD is considered the pathological hallmark of
DSP [6–8]. There is some uncertainty as to whether IENFD
differentiates between patients with painless and painful DSP,
as some studies report an inverse correlation between IENFD
and pain [9], while others report no correlation [10].
Morphometric analysis of nerve fibres detects a change in
axonal structures termed axonal swellings, a degenerative
change that contains watery axoplasm, neurofilaments and
abnormal mitochondria [11]. It is postulated that axonal swell-
ings, in particular larger swellings, precede small fibre degen-
eration [12, 13]. In patients with DSP the relationship of
axonal swellings to polyneuropathy progression and symp-
toms is unclear. In one study an increase of axonal swellings
was found in patients with painful DSP [5]; however, in
another study axonal swellings did not differentiate between
patients with painful and painless DSP [14]. In both studies,
axonal swellings were higher in participants with DSP when
compared with participants with diabetes but without DSP,
and with healthy control (HC) participants.
Therefore, it is unclear if axonal swellings are related to
type 2 diabetes, DSP or neuropathic pain.
This study investigates whether the axonal swelling ratio
(axonal swellings/intraepidermal nerve fibres) is related to
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DSP, neuropathic pain and clinical variables in a well-
characterised and comprehensively phenotyped cohort of
study participants with type 2 diabetes mellitus and HC partic-
ipants [10, 15].
Methods
Standard protocol approvals, registrations and
patient consents
The data presented in this paper are derived from the Pain in
Neuropathy Study (PiNS) from the UK and the International
Diabetic Neuropathy Consortium (IDNC) study from Aarhus,
Denmark. PiNS is a multicentre study approved by the
National Research Ethics Service of the UK (No.: 10/
H0706/35). The IDNC study was approved by the regional
ethics committee (No.: 1-10-72-130-16). All study partici-
pants signed written consent forms, in line with the
Declaration of Helsinki, before enrolment.
Study protocol
All participants underwent a medical history review and a
structured neurological examination. Study participants
underwent nerve conduction studies, skin biopsy for
IENFD assessment, quantitative sensory testing and
diabetes-related biochemistry testing including a single
HbA1c test at the time of study. The clinical examination
is described in detail elsewhere [10, 15]. The Toronto
Clinical Scoring System (TCSS) score was calculated for
all participants [16]. TCSS score is used as a surrogate
measure of neuropathy severity, and was not used in the
diagnosis of DSP.
Participant selection
A total of 249 study participants were recruited as part of two
different studies, 204 participants with type 2 diabetes and 45
HC participants without diabetes. Clinical assessment,
polyneuropathy grading, neuropathic pain grading and skin
staining were performed uniformly using the same methodol-
ogy. A subset, 142 of the participants (57.0%), were part of the
PiNS study, and all were diagnosed with type 2 diabetes [10].
The remaining 107 participants, 62 individuals with type 2
diabetes and 45 HC participants, were part of the IDNC study
[15] (Electronic supplementary material [ESM] Fig. 1). A
detailed description of the clinical assessment and phenotyp-
ing of the study participants can be found elsewhere and will
be briefly described here [10, 15].
Selection of IDNC participants
IDNC participants were part of a clinical study of 389 patients
conducted in 2016–2018, initially recruited from a question-
naire study on neuropathy and pain of 5514 recently diag-
nosed individuals with type 2 diabetes from the Danish
Centre for Strategic Research in Type 2 Diabetes (DD2) [15,
17]. Exclusion criteria were cognitive impairment, language
difficulties and pregnancy. For more details see references
[15, 17].
Of the 389 patients included at the two IDNC study sites
(Aarhus and Odense), 49 were excluded with other causes of
neuropathy and significant non-neuropathic pain. We then
randomly selected 62 type 2 diabetes participants and 45 HC
participants who were included in Aarhus where IENFD and
nerve conduction study data were available (ESM Fig. 1).
We ensured that the included HC participants without
diabetes, recruited from within the patients’ social circle and
by invitational flyers, were as close as possible to the diabetic
participants in terms of age and sex. Exclusion criteria for HC
participants were diabetes, severe chronic illness, psychiatric
or neurologic illness, chronic pain or intake of any pain medi-
cation within 3 days before inclusion [15]. HbA1c and blood
glucose were measured for all HC participants to exclude
diabetes (Table 1).
Selection of PiNS participants
PiNS is an observational cross-sectional multicentre study in
which study participants were recruited from primary care
practices in London and Oxford, and from tertiary clinics in
Oxford, London and Sheffield. Patients with diabetes mellitus
aged above 18 years with diagnosed DSP, or patients with
symptoms and signs suggestive of DSP, were included.
Exclusion criteria were pregnancy, coincident major psychi-
atric disorders, poor or no English language skills, severe pain
at recruitment from a cause other than DSP, documented
central nervous system lesions or insufficient mental capacity
to provide informed consent or to complete questionnaires.
The PiNS participants included in this study were participants
with both IENFD and nerve conduction study data.
Nerve conduction studies
Nerve conduction tests were performed with an ADVANCE
system (Neurometrix, Waltham, MA, USA) (PiNS study) or
Keypoint.Net EMG equipment (Dantec, Skovlunde,
Denmark) (Aarhus) and we used conventional reusable elec-
trodes. We performed conventional nerve conduction studies
of sural nerves bilaterally and the median, peroneal and tibial
nerves unilaterally [18]. If the median nerve was found to be
abnormal, the ulnar nerve was examined on the same side.
The results were compared with laboratory controls using z
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scores. Polyneuropathy was defined as ≥2 nerves with ≥1
abnormal measure, including at least one abnormal sural nerve
[18].
Skin biopsy
Skin biopsy and stainingAll biopsy samples for determination
of IENFD were taken in accordance with the consensus docu-
ment produced by the European Federation of Neurological
Societies and the Peripheral Nerve Society Guideline on the
utilisation of skin biopsy samples in the diagnosis of periph-
eral neuropathies [7, 10]. Skin biopsies were taken 10 cm
proximal to the lateral malleolus. The biopsies were fixed
overnight in 2% fresh periodate-lysine-paraformaldehyde.
After cryoprotection the samples were embedded in optimal
cutting temperature (OCT).
For analysis under brightfield microscopy, 50 μm thin
sections were used, and immunohistochemistry for protein
gene product 9.5 (PGP 9.5) was performed on free-floating
sections using the immunoperoxidase method. The primary
antibody was a rabbit anti-PGP 9.5 antibody (1:15,000;
Ultraclone, Yarmouth, Isle of Wight, UK or 1:1000;
Zytomed, Dusseldorf, Germany). The secondary antibody
was a biotinylated goat anti-rabbit IgG (1:400; Vector
Laboratories, Burlingame, CA, USA).
Analysis PGP 9.5-immunoreactive nerve fibres crossing the
basal membrane of the epidermis were counted under a dry
×40 objective and a measurement of the epidermal length of
the sample was obtained. IENFD was assessed using a double
brightfield microscope using established counting rules and
was expressed as fibres per millimetre of epidermal length.
IENFD was considered abnormal if below the fifth centile
for age- and sex-matched HC participants [19]. Axonal
swellings were measured using newCAST stereological soft-
ware Version 2019.2 (Visiopharm, Hoersholm, Denmark) and
quantified using a light microscope under a ×60 oil objective
(Olympus BX51 microscope, Olympus, Japan). Axonal swell-
ings were defined as enlargements on epidermal-penetrating
nerve fibres exceeding 1.5 μm in diameter and could be located
anywhere on the nerve fibre, distally or proximally; i.e. located
in the epidermal part of the fibre or in the dermal part [12, 20,
21]. There is currently no consensus on how to define axonal
swellings, but the majority of studies define them either as
enlargements exceeding 1.5 μm in diameter, as done here, or
by counting swellings that exceed at least three or five times the
diameter of the afferent nerve fibre. The 1.5 μm method was
chosen as we believe it to be the more reliable measure of the
two methods, requiring fewer measurements and calculations
and thus reducing error rates. Axonal swelling ratio was obtain-
ed by dividing the number of swellings by the number of
intraepidermal nerve fibres. Both IENFD and axonal swellings
were counted in a blinded fashion.
The diagnosis of definite DSP and definite painful DSP
DSP was defined according to the Toronto Diabetic
Neuropathy Expert Group [22] and painful DSP according
to the Neuropathic Pain Special Interest Group (NeuPSIG)
criteria [23] for neuropathic pain.
The following criteria were used for neuropathy and neuro-
pathic pain grading of participants from both cohorts.
No DSP Study participants with no possible clinical neuropa-
thy, normal nerve conduction studies and normal IENFDwere
defined as not having a DSP.
Possible clinical neuropathy is defined as the presence of
symptoms and/or signs of neuropathy, including any one or
Table 1 Demographics of study participants
Characteristic HC (n = 45) DSP− (n = 31) Painless DSP+ (n = 74) Painful DSP+ (n = 99) p value
Age, years 62.2 (55.3–68.4) 62.6 (51.1–68.2) 67.9 (60.1–72.9) 66.4 (57.4–71.6) 0.008
Sex, female (%) 25 (55.6) 16 (51.6) 43 (58.1) 60 (60.6) 0.83
BMI, kg/m2 25.4 (22.8–28.1) 30.5 (25.3–34.3) 31.4 (26.9–35.7) 33.1 (28.1–37.9) <0.001
Duration of type 2 diabetes, years 5.9 (3.8–7.9) 10.6 (6.0–17.5) 12.0 (6.0–18.9) 0.001
HbA1c
mmol/mol 37.0 (35.0–39.0) 50.0 (46.0–57.0) 52.0 (45.7–61.5) 58.0 (50.0–69.0) <0.001
% 5.5 6.7 6.9 7.5
TCSS total score (0–19) 1.0 (0.0–2.0) 1.0 (0.0–3.0) 8.0 (6.0–10.0) 11.0 (8.0–14.0) <0.001
Data are shown as median (IQR) and analysed byKruskal–Wallis. Categorical data are shown as numbers (percentages) and analysed by Pearson χ2 test
of association
HbA1c is reported both in SI units (mmol/mol) and in percentages (NGSP: National Glycohemoglobin Standardization Program)
Detailed baseline characteristics for the original study cohorts in whole (PiNS and IDNC) are provided in previous studies [10, 15]
Missing data: BMI: 0.8%; duration of diabetes: 1.2%; HbA1c: 2.8%; TCSS score: 0.4%
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more of the following: neuropathy symptoms (decreased
sensation, positive sensory symptoms, e.g. burning, aching
pain) mainly in the toes, feet or legs; decreased distal sensa-
tion; or decreased/absent ankle reflexes [22].
Definite DSP Study participants with at least a possible clinical
neuropathy and abnormalities on either nerve conduction
studies or IENFD were defined as definite DSP.
Painful DSP Definite painful DSP was defined in line with
NeuPSIG criteria [23], i .e. neuropathic pain in a
neuroanatomically plausible distribution, feet and/or hands,
in participants with DSP.
Statistical analysis
We used STATA version 14 (StataCorp, TX, USA) for data
analysis. Data are reported as medians with IQR. Data were
compared across the three groups with Kruskall–Wallis test or
between two groups with Mann–Whitney U test. Categorical
data were analysed with χ2 test of association. Spearman’s
rank correlation analyses were performed to explore associa-
tions between swelling ratio and diabetes-related biochemical
variables, e.g. HbA1c. Significance was set at p < 0.05.
All comparisons between groups were performed twice: (1)
all study participants; and (2) only participants with IENFD
greater than 1 fibre/mm. The IENFD cut-off of 1 was set prior
to statistical analyses since it was felt from our experience that
axonal swellings with lower IENFD (<1) could not be reliably
counted without potential bias of our outcomes.
Results
Study participants
A total of 249 study participants were included. The study
included four groups: (1) HC participants, n = 45; (2) DSP−,
n = 31; (3) DSP+, which were divided into painful and pain-
less DSP+, n = 99 and n = 74, respectively (ESM Fig. 1, ESM
Table 1).
The characteristics of the groups are shown in Table 1.
Participants in the painful DSP+ group had the highest
TCSS scores, HbA1c levels and BMI and the longest diabetes
duration.
IENFD and swelling ratios
There was a difference in IENFD and swelling ratios between
the groups (Table 2, Fig. 1a,b, ESM Fig. 1). IENFD was
decreased in DSP+ participants when compared with DSP−
participants and HC participants. There was no difference
between painless DSP+ and painful DSP+ participants (p =
0.08). Specifically, median (IQR) IENFD (fibres/mm) was:
6.7 (5.2–9.2) for healthy control participants; 6.2 (4.4–7.3)
for DSP−; 1.3 (0.5–2.2) for painless DSP+; and 0.84 (0.4–
1.6) for painful DSP+. The above differences remained when
only participants with IENFD > 1.0 fibre/mm were included.
The axonal swelling ratio was significantly higher in DSP−
participants when compared with all DSP+ (painless and pain-
ful) patients and HC participants (Table 2). Figure 2 shows a
representative image of axonal swellings.
If the IENFD is very low (as can be the case in DSP+), it is
not possible to reliably calculate the swelling ratio because so
few intraepidermal nerve fibres are sampled. A total of 86
study participants (out of 249) had IENFD ≤ 1 fibre/mm: 31
(41.9%) painless DSP+ participants and 55 (55.6%) painful
DSP+ participants. When the participants with IENFD ≤ 1
fibre/mm were excluded, the median swelling ratios for pain-
less DSP+ and painful DSP+ participants increased from 0.0
to 0.3 and 0.13, respectively (Table 2, Fig. 1b). Therefore, the
axonal swelling ratio was higher in study participants with
type 2 diabetes, irrespective of whether DSP was present,
when compared with HC participants. The axonal swelling
ratio increased in participants with type 2 diabetes with higher
IENFD (Fig. 1c), but not in the HC participants (Fig. 1d).
Table 3 shows the correlation between clinical variables
and swelling ratio in the study participants. The difference
observed when including all study participants disappears
when excluding patients with IENFD ≤ 1, leaving only a weak
correlation to HbA1c; this suggests that the difference was
driven by the fact that participants with low IENFD are unlike-
ly to have swellings present (Table 3). Specifically, the axonal
swelling ratio correlated weakly with HbA1c (r = 0.16, p =
0.04), but did not correlate with the Toronto Clinical
Scoring System (surrogate measure of DSP severity), BMI
or type 2 diabetes duration.
Discussion
In this study, we addressed the question of whether axonal
swellings are related to type 2 diabetes, DSP or neuropathic
pain. Our key findings are that where IENFD > 1.0 fibre/mm,
the axonal swelling ratio is increased in type 2 diabetes when
compared with HC participants; axonal swelling ratio did not
differ between study participants with or without painless
DSP+, or between painless DSP+ and painful DSP+. There
was a weak correlation between axonal swelling ratios and
HbA1c but not other clinical variables. These findings indicate
that patients with type 2 diabetes with preserved
intraepidermal nerve fibres have more axonal swellings
compared with HC participants; however, the presence of
axonal swellings is not associated with DSP or neuropathic
pain. This suggests that axonal swellings are pathological and
an early marker of sensory neuron injury in type 2 diabetes.
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Axonal swellings have been defined and quantified in
different ways. Hence, direct comparison between studies is
difficult. Axonal swellings in this study were defined by
absolute measurements of 1.5 μm [14], and not by their size
relative to adjoining nerve fibres [5, 13]. We found, as did
Cheung et al. [14], no axonal swelling ratio difference
Table 2 IENFD and swelling
ratio for all study participants and
for those with IENFD > 1.0 fibre/
mm
Variable HC DSP− Painless DSP+ Painful DSP+ p value
All study participants, N = 249
n 45 31 74 99
Swelling ratio 0.03 (0.0–0.13) 0.35 (0.17–0.59) 0.0 (0.0–0.45) 0.0 (0.0–0.24) <0.001b
IENFD 6.6 (5.3–9.0) 6.2 (4.4–7.3) 1.3 (0.5–2.2) 0.8 (0.4–1.6) <0.001a/b
Swellings, n (%) 25 (55.6) 30 (96.8) 32 (43.2) 32 (32.3) <0.001b
IENFD >1 fibre/mm, n = 163
n 45 31 43 44
Swelling ratio 0.03 (0.0–0.13) 0.35 (0.17–0.59) 0.30 (0.0–0.57) 0.12 (0.0–0.36) <0.001a/b
IENFD 6.6 (5.3–9.0) 6.2 (4.4–7.3) 2.1 (1.6–3.2) 1.7 (1.4–2.8) <0.001a/b
Swellings, n (%) 25 (55.6) 30 (96.8) 27 (62.8) 23 (52.3) <0.001b
Data are shown as median (IQR)
Swellings: n (%) for swellings represents the number and percentage of patients who had at least one swelling
present on an intraepidermal nerve fibre
Swelling ratio: number of swellings/number of intraepidermal nerve fibres
aHC participants vs patients with type 2 diabetes (DSP−, painless DSP+, painful DSP+)
bDSP− vs painless DSP+ and painful DSP+
Fig. 1 Skin biopsy results. (a)
IENFD for all participants. (b)
Swelling ratio for all participants
(light blue) and those with
IENFD >1 (dark blue). (c, d) four
different IENFD cut-offs in (c)
patients with type 2 diabetes and
(d) HC participants
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between those with painless DSP and those with painful DSP.
In contrast, the studies that defined axonal swellings relative to
adjoining nerve fibres, as 3–5 times the diameter of the afferent
nerve fibre, found an association between axonal swellings and
symptomatology [5, 13]. Therefore, studies that used axonal
swellings relative to axon fibre saw an association with symp-
tomatology, while studies using an absolute size cut-off did
not. The reason for these differences is unclear. Such a finding
highlights the importance of reaching a consensus on swelling
definition and how this should be quantified andmeasured.We
used an absolute cut-off value of 1.5 μm as it is more reliable
than multiple measurements of the afferent fibre. Indeed, elec-
tron microscopy studies show that C fibre diameters in 95% of
HC participants are less than 0.5 μm, with some as low as
0.2 μm. Therefore, in our study the axonal swellings are at
least three times the upper limits of normal of healthy C fibres
[24]. Lastly, the discrepancy between our findings and other
studies may be due to differences in clinical variables such as
age or diabetes duration [5, 13].
Our findings may indicate that axonal swellings are related to
type 2 diabetes rather than to DSP and neuropathic symptoms.
There is a weak correlation to single-point HbA1c and no corre-
lation to type 2 diabetes duration or BMI. It is likely that axonal
swellings are a sign of nerve injury. A longitudinal study track-
ing the development of DSP, symptoms and axonal swellings is
needed to determine the natural history of axonal swellings and
their relationship toDSP and neuropathic pain. It is also not clear
what pathological process causes axonal swellings.
Axonal swellings are present in skin biopsies fromHC partic-
ipants, but are clearly higher in patients with polyneuropathies [5,
14, 20]. Axonal swellings are described in patients with
AIDS/HIV [11, 12], pure small fibre neuropathy [21], distal
symmetric polyneuropathy of various aetiologies [20], idiopathic
neuropathic pain [11–14, 20], bortezomib-induced neuropathy
[25] and amyotrophic lateral sclerosis (ALS) [26, 27], and in
myelinated nerve fibres of patients with Charcot–Marie–Tooth
disease [28]. Axonal swellings may be associated with dysfunc-
tional axonal transport and future nerve fibre loss, ormay even be
a potential biomarker of axonal regeneration [5, 12]. Detailed
electron microscopy analysis of axonal swellings could yield
insights into their potential mechanism, but needs technical
modifications in how skin biopsies are processed.
This study has a number of strengths and limitations. Our
study consisted of a large cohort of individuals with type 2
diabetes that were well phenotyped. All participants were
examined by a clinician and underwent multiple tests to
confirm the presence or absence of polyneuropathy and neuro-
pathic pain. Our approach of clinical assessment followed by
confirmatory investigations is the current gold standard and
most rigorous approach for the diagnosis of polyneuropathy
and neuropathic pain. Limitations include the retrospective
study design, participants from two distinct study sites and
unequal distribution among subgroups. The axonal swelling
ratio was only different when IENFD >1 fibre/mm, thus limit-
ing its role in the diagnosis of DSP, where IENFD is often
lower. However, this does not negate the importance of study-
ing axonal swellings to improve our understanding of early
morphological abnormalities in diabetic neural dysfunction.
Lastly, the findings in this study are applicable to type 2 diabe-
tes only, as no patients with type 1 diabetes were included.
Conclusion
We have shown in a large cohort of well-characterised partic-
ipants that skin biopsies from participants with type 2 diabetes
have higher axonal swelling ratio compared with skin biopsies
Epidermis
Dermis
Fig. 2 A representative image of axonal intraepidermal nerve swellings,
highlighted by the arrows. The dashed line represents the division
between the epidermis and dermis. Scale bar, 10 µm
Table 3 Correlation between swelling ratio and clinical characteristics,









Sex, female 0.02/0.70 0.02/0.83
Age, years −0.03/0.68 0.04/0.60
BMI, kg/m2 −0.07/0.22 0.06/0.45
HbA1c, mmol/mol −0.09/0.17 0.16/0.04
TCSS score −0.15/0.02 0.07/0.40





from healthy study participants, independent of DSP, if
IENFD >1 fibre/mm. Axonal swelling ratio was weakly asso-
ciated with HbA1c levels but not with neuropathy severity,
BMI or diabetes duration.
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